GlaxoSmithKline to acquires Genelabs Technologies for $57M

I’m a huge fan of early stage deals with lots of upside and a cost under $75M.
GlaxoSmithKline, looking to shore up their hepatitis C pipeline, announced that they have entered into an agreement with Genelabs Technologies for approximately $57 million (£35 million) through a tender offer of $1.30 per share in cash.

View the full GNLB [...]

GlaxoSmithKline and AFFiRiS Ink Alzheimer’s Disease Vaccine Deal

GlaxoSmithKline Biologicals and AFFiRiS GmbH announced the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS’s Alzheimer’s disease vaccine programmes, aimed at treating Alzheimer’s by targeting beta-amyloid.
As part of the agreement, GSK is acquiring exclusive rights to develop and commercialise two Alzheimer’s disease vaccine candidates that are based on AFFiRiS AFFiTOPE technology and [...]

GSK and Cellzome Announce Alliance over Kinase Technology

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads(TM), a proprietary technology for screening and profiling kinases in relevant cells and tissues.
Under the agreement GSK has exclusive options to license drug candidates from Cellzome’s kinase programs directed [...]

BMS Offers to Buy The Rest of ImClone

In a regulatory filing this morning, Bristol-Myers Squibb announced it has offered to buy the 83% of ImClone it doesn’t already own for an all cash, $60/share or $4.5B. This offer represented a 30% premium over yesterday’s close but already in premarket trading, ImClone has hit $65/share.
I’ve been trying to figure BMS out for [...]

Big Pharma Tries to Shake Things Up

Image by Getty Images via Daylife

GSK to shake-up research strategies (Financial Times)
UCSF, Pfizer sign collaborative research deal (San Fransisco Chronicle )
Both Via Pharmalot
It’s no secret that big pharma players have some work to do on their late-state pipeline and that they are collectively grasping at straws trying to bring in revenue.
Clearly, deciding to reorganize your [...]

Financing for Concert Pharmaceuticals

CoNCERT Pharmaceuticals, Inc. Raises $37 Million in Series C Financing
CoNCERT Pharmaceuticals, Inc., announced the closing of a $37 million Series C financing today. The Company intends to use the proceeds to further advance its deuterium chemistry platform and product pipeline. The financing was led by a leading public equity institutional investor and included participation [...]

GlaxoSmithKline Buys Sirtris for $720M

GSK just paid $720M (22.50/share or an 84% premium) for a company with one phase II compound that… well… wasn’t shy about publicizing itself. Take this quote from CEO Chris Westphal for instance, “the first group to have ever targeted an anti-aging gene to treat a disease of aging.” Aside from being not [...]

Treximet… Finally!

I’ve been having migraines lately, well for the last few years. Terrible migraines. Migraines so debilitating only a combination of acutely acting medicines could even touch the pain. The problem was, up until now (finally, after a two year delay), I had to open two bottles of medicine, remove a few pills [...]